Insider Buying: Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) CFO Acquires $54,999.45 in Stock

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) CFO Gordon Dunn acquired 122,221 shares of Quoin Pharmaceuticals stock in a transaction that occurred on Monday, December 23rd. The stock was bought at an average price of $0.45 per share, for a total transaction of $54,999.45. Following the completion of the acquisition, the chief financial officer now owns 151,077 shares in the company, valued at $67,984.65. This trade represents a 423.55 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Quoin Pharmaceuticals Stock Performance

Quoin Pharmaceuticals stock opened at $0.55 on Monday. The company’s 50 day simple moving average is $0.68 and its 200-day simple moving average is $0.63. Quoin Pharmaceuticals, Ltd. has a 1 year low of $0.43 and a 1 year high of $6.18. The company has a market capitalization of $2.78 million, a price-to-earnings ratio of -0.14 and a beta of 1.79.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.